News Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Market Closed - Nyse Other stock markets 04:00:01 2024-05-03 pm EDT			5-day change	1st Jan Change
7.82 ^USD	-3.34%		-10.22%	-2.49%

May. 03	RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	MT
May. 02	Bausch Health Shares Fall Following Q1 Results	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	May. 03	MT
Bausch Health Announces First Quarter 2024 Results	May. 03	AQ
Bausch Health Shares Fall Following Q1 Results	May. 02	MT
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance	May. 02	MT
Transcript : Bausch Health Companies Inc., Q1 2024 Earnings Call, May 02, 2024	May. 02
Bausch: Q1 Earnings Snapshot	May. 02	AQ
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance	May. 02	MT
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis	May. 02	MT
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
North American Morning Briefing : Stock Futures -2-	May. 02	DJ
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	May. 01	MT
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	May. 01	MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	May. 01	MT
Bausch + Lomb Brief: Q1 Revenue of US$1.099 Billion; GAAP Net Loss Attributable of $167 Million	May. 01	MT
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes	Apr. 25	MT
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes	Apr. 25	MT
Bausch Health in 'Stronger Position' for Bausch + Lomb Distribution, RBC Says	Apr. 23	MT
RBC Previews Bausch Health's Q1, Trims Target to US$11	Apr. 23	MT
RBC Trims Price Target on Bausch Health to $11 From $12, Keeps Sector Perform Rating	Apr. 23	MT
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1	Apr. 22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Summary

Filters